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Cancer development and progression is a multi-stage process invol-
ving dynamic changes within the genome. Common features of
cancer cells include uncontrolled proliferation, self-sufﬁciency in
growth, escape from cell death and the acquisition of immortality.
Understanding the different molecular routes that lead to a malig-
nant phenotype is the key to identifying speciﬁc molecular targets
to selectively kill cancer cells.
This meeting concentrated on the contribution of transcription
modulators, oncogene activation and genomic instability to the
cancer phenotype. This led onto the impact of microarray technol-
ogy on genetic proﬁling of the disease and how this combined
knowledge is being exploited to improve diagnosis and develop
novel anti-cancer drugs.
TRANSCRIPTION MODULATORS AND ONCOGENES
Deregulation of gene expression is a common feature in all cancer
cells and is dependent on extensive chromatin remodelling within
the genome. Local chromatin structure is strongly inﬂuenced by
the post-translational modiﬁcation of the core histones. Tony
Kouzarides (Cambridge) talked about chromatin modifying
enzymes, focusing speciﬁcally on the regulation of Lysine 9 (K9)
on histone H3. Using both mammalian and yeast models he
described how the transcriptional repressor pRb silences gene tran-
scription in a two stage process. Initially pRb and a histone
deacetylase protein (HDAC) function to deacetylate K9 on H3.
pRb subsequently interacts with the Suv39 and HP-1 proteins
and K9 on H3 is methylated as a secondary step. This talk gave
an insight into how pRb, depending on the proteins it associates
with, can function to either deacetylate or methylate chromatin.
Pier Giuseppe Pelicci (Italy) addressed the function of the
retinoic acid receptor (RAR) which can function either to repress
transcription or in the presence of ligand, to mediate acetylation
through recruitment of co-activators. His talk focused on acute
myelocytic leukaemias, which are characterised by the presence of
RAR mutants. In some sub-groups of leukaemias the mutant RAR-
fusion protein, generated by translocation, results in a block in differ-
entiation and inhibition of apoptosis through association of the RAR-
fusion protein with an HDAC protein. However, the vast majority of
these leukaemias are sensitive to treatment with retinoic acid (RA)
who’s purpose is to disrupt the HDAC–RAR-fusion interaction
resulting in activation of genes necessary for the differentiation
process. In contrast to this, other subgroups of leukaemias where a
distinct RAR-fusion protein is generated are no longer sensitive to
RA alone. This is due to RA being unable to displace the HDAC
protein from this speciﬁc RAR-fusion resulting in a continued block
in differentiation. Pilot studies in acute myeloid leukaemia (AML)
patients combining RA treatment with HDAC inhibitors were
observed to induce differentiation in all the cases tested and has lead
to the hypothesis that HDACs may be putative targets for differentia-
tion treatment of AMLs that are resistant to RA treatment alone. Both
of these talks gave supporting evidence that defects in chromatin
modiﬁcation may contribute to a number of human malignancies.
Therefore, understanding the complexes regulating the state of chro-
matin in the cell may, as in the case of AML, modify our current
treatments for certain groups of cancers.
A hallmark of cancer is the activation of speciﬁc subsets of genes
involved in promoting proliferation. Consequently, the activation
of a catalogue of transcription factors have been associated with
cancer. The AP-1 transcription factor has been implicated in a
number of biological processes and Erwin Wagner’s (Vienna) talk
described the function of AP-1 in mouse development and cancer.
Studies using conventional and conditional knock-outs have
revealed that some components of the AP-1 complex such as c-
Fos, FosB and JunD are dispensable for embryonic development,
whereas others like c-Jun, JunB and Fra-1 are essential for embryo-
nic development or adult viability. c-Jun was demonstrated to be
essential for the proliferation of ﬁbroblasts and hepatoblasts,
whereas JunB functions as a negative regulator of proliferation
through transcriptional activation of the cyclin dependent kinase
inhibitor p16. In contrast to the role for Jun proteins in cell prolif-
eration, the Fos proteins were described by Wagner as clear
determinants of bone development. Previous in vitro studies have
demonstrated that c-Fos, unlike Fra-1 or Fra-2 has the ability to
transform ﬁbroblasts in culture and this more tumorigenic pheno-
type of the Fos proteins was mirrored in these transgenic mouse
studies. Fra-1 transgenic mice developed osteosclerosis due to
enhanced differentiation of bone matrix whereas c-fos transgenic
mice develop osteosarcomas.
Tom Curran (Memphis) also addressed the role of fos in cellular
transformation. This work was based on studies demonstrating a
reduction in tumour progression and invasion in a TPA skin
model performed in c-fos knock out mice. Using a transcriptional
proﬁling approach he has focused on isolating fos target genes that
are responsible for this transformed phenotype.
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tumorigenesis, the inappropriate survival of cancer cells also plays a
major role in this process. The NFkb transcription factor is an
anti-apoptotic factor that plays an important function in tumour
development by providing a link between inﬂammation and
cancer. Several studies have suggested that chronic inﬂammation
during cancer treatment may activate NFkb providing a survival
signal that can contribute to resistance to speciﬁc cancer therapies.
Michael Karin (California), the keynote speaker, used NFkb to
introduce the concept of modulating transcription factor activity
to enhance the cancer cell’s response to apoptosis inducing drugs.
John Sedivy (Rhode Island) expanded this concept by describing a
novel regulation of NFkb by the Raf kinase inhibitor protein
(RKIP). Microinjection studies revealed that RKIP neutralising
antibodies can activate NFkb, an effect that is independent of
the previously described role for RKIP in inhibiting Raf/MEK
signalling. Sedivy demonstrated that RKIP inhibited IKKa and IKKb
kinase activities, potentially via a direct interaction with the
upstream kinases TAK1 and NIK1. Studies with prostate cancer cell
lines revealed that resistance to apoptosis correlated with loss of
RKIP expression in these tumour models. This suggests that RKIP
functions in blocking the survival signal propagated from NFkb.
Ron Hay (St Andrews) further described a role for NFkb activa-
tion in cancer cells. Hodgkins lymphoma (HL) is characterised by
constitutive NFkb activity which arises from at least three known
mechanisms. In some cases it is due to EBV transformation. Other
non-EBV transformed HL’s achieve constitutive NFkb activity due
to deletion of the NFkb inhibitor Ikba, or constitutive activation
of the IKKa and IKKb kinases. Studies with a super-repressor of
the NFkb inhibitor Ikba, result in the induction of apoptosis in
HL derived cell lines suggesting that resistance to cell death may
be due to constitutive NFkb activity. Microarray analysis is
currently being applied to HL cell lines that are sensitive to apop-
tosis and those that show resistance to apoptosis to identify
potential activators of NFkb. Both of these talks gave insights into
how the modulators of NFkb are being targeted in the context of
the cancer cell to understand how these cells avoid apoptotic
signalling events.
GENOMIC INTEGRITY: DNA REPAIR AND TELOMERE
MAINTENANCE
Loss of genomic integrity is a primary feature of cancer. Recent
evidence suggests that defects in DNA maintenance pathways and
telomere dysfunction promote genomic instability and drives devel-
opment of the disease. Stephen Jackson (Cambridge) focused on
key players involved in the detection and repair of double stranded
breaks (DSB). Clues to the role of the DNA damage sensors, ATM
(ataxia telangiectasia mutated) and ATR (ataxia telangiectasia
related) kinases, their cell cycle targets and role in DSB repair were
aided by the identiﬁcation of three genes involved in cancer prone
human disorders. The ATM gene in ataxia telangiectasia (AT), the
MRE11 gene in an ataxia telangiectasia-like disorder (ATLD) and
defects in the NSB1 gene which are associated with the Nijmegen
breakage syndrome. The common features of these three conditions
include hypersensitivity to ionising radiation, S-phase checkpoint
defects, impaired telomere function and increased genomic
instability. The NSB1 protein is one of the components of a larger
complex, RAD50/MRE11/NSB1 which is involved in ‘cleaning up
DSB’ in preparation for repair. Evidence obtained from deletion
analysis of the analogous yeast complex (XRM) demonstrated its
involvement in S-phase control in response to replication stalling
and DSB. This led to a model whereby this complex, common
to both homologous recombination (HR) and non-homologous
end joining (NHEJ) repair pathways, has a role in ampliﬁcation
of weaker DNA damage signals. In response to these weak signals
the XRM complex is recruited to the site of the break and the
nuclease activity of Mre11 leads to recruitment and activation of
Tel1p, the yeast ATM homolog, possibly by a co-factor analogous
to the DNA targeting role of Ku70-Ku80 in DNA-PK complex.
Tel1p then functions to phosphorylate its targets both within this
complex and downstream cell cycle targets such as p53. This model
helps explain the observation that cells isolated from AT and ATLD
patients are hypersensitive to low doses of radiation.
Telomere maintenance is essential for tumour cells to by-pass
replicative senescence and become immortal. Approximately 80%
of human tumours and 99% of immortal cells stabilise their telo-
meres by activation of the enzyme telomerase. One of the current
models suggests that during the proliferative stages of tumour
development there is progressive telomere errosion that leads to
short dysfunctional telomeres. In the absence of senescence and
DNA damage checkpoints this telomere dysfunction drives geno-
mic instability. The reactivation of telomerase, restores
chromosomal stability by maintaining short by stable telomeres
and drives the immortal phenotype. Maria Blasco (Madrid)
provided in vivo data from mice deﬁcient in the telomerase RNA
component (Terc
7/7) and compound knock-outs with tumour
prone backgrounds to support this model. Interestingly late genera-
tion Terc
7/7 mice with critically short telomeres were also
relatively resistant to chemically induced skin papillomas, leading
to the hypothesis that critically short telomeres triggers a DNA
damage response and activates p53 preventing tumour progression
via growth arrest or apoptosis. However, a potential pitfall of this
approach is that blocking telomerase may lead to the activation of
alternative telomere maintenance (ALT) pathways or may require
an intact p53 response.
Murray Robinson (Amgen) presented encouraging data on the
molecular response to telomerase inhibition. The introduction of
an inducible telomerase dominant negative into two p53 deﬁcient
tumour cell lines with differing telomere lengths, had very distinct
outcomes. In A431 cells, which have short telomere lengths, apop-
tosis was induced after only 3–4 days with no evidence of
activation of ALT pathways. In contrast, 293T cells which have
varying telomere lengths displayed reduced viability but no induc-
tion of apoptosis and reactivated telomerase. Using microarray
analysis the growth arrest and DNA damage (GADD) genes,
GADD45 and GADD153, were found to be up-regulated prior to
the activation of apoptosis in A431 cells. GADD45 gamma was
preferentially induced in A431 cells in response to telomere inhibi-
tion and it induced the expression of GADD153, which mediates
the apoptotic responses or growth arrest when GADD153 is
knocked out. In contrast, 293T cells constitutively express GADD45
gamma and have adapted to bypass this pathway to cell death.
293T cells harbour the adenovirus E1B 19K protein which is an
anti-apoptotic homologue of Bcl-2 and therefore may not be
typical of most human carcinomas. However, the clinical signiﬁ-
cance of this p53-independent GADD mediated apoptosis
pathway will depend on how well utilised this pathway is in p53
deﬁcient tumours in vivo. If the majority of cancers show a similar
response to A431 cells then telomerase inhibitors have great poten-
tial, but if most tumours display properties similar to 293T cells
then a combinational therapeutic approach may be necessary.
Direct links between telomere dysfunction and the DNA repair
pathways are starting to emerge. In yeast and mammalian systems
components of the DNA repair pathways, RAD50/MRE11/NSB1,
DNA-PK and its targeting component Ku are associated with the
ends of chromosomes and relocalise to the sites of double strand
breaks. Defects in the DSB repair pathway can lead to dysfunc-
tional telomeres as alluded to by Stephen Jackson. To address
the role of these DNA repair proteins in the context of telomere
maintenance, Maria Blasco examined telomere lengths in mice deﬁ-
cient in Ku86 or DNA-PKcs. Ku86 deﬁcient cells display a more
acute telomeric phenotype than DNA-PKcs deﬁcient cells showing
higher rates of telomere-telomere fusions. Surprisingly, Ku86 deﬁ-
cient cells have slightly elongated telomere ends at the fusion
points compared to DNA-PKcs. It was proposed that mammalian
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with the telomere binding proteins TRF1 and TRF2 at T-loop
structures creating a tight cap around the telomere end. In the
absence of Ku86 the cap is slackened and allows telomerase and
DNA repair activities access to elongate and fuse telomeres respec-
tively. This suggests that dysfunctional telomeres can be generated
in different ways. Telomeric attrition results in short telomeres at
the fusion points whereas loss of telomere protective function via
loss of Ku86, DNA-PKcs results in long telomeres at the fusion
points.
A theme which persisted throughout the talks on DNA damage
and telomere function is the need to rethink our approaches to
therapeutic strategies. While previously the main thrust of research
has focused on modulating p53 activity in tumours, data is now
beginning to emerge suggesting that p53, DNA damage pathways
and telomere maintenance are all interlinked processes and that
we should be considering combined intervention approaches to
target the cancer cell.
THERAPEUTIC TARGETS
The selective activation of telomerase and inactivation of p53 in the
majority of cancers has lead to therapeutic strategies based on inhi-
bition of telomerase (as discussed above) in addition to reactivating
p53. The p53 protein plays a central role in maintaining genomic
integrity by responding to a variety of DNA damage signals and
inducing cell cycle arrest or apoptotic cell death. Testimony to
the success of p53 as a tumour suppressor is that the vast majority
of human tumours have either a mutated p53 gene or defects with-
in p53 signalling pathways. Preliminary therapies were based on
reactivating p53 directly, but more recently the focus has been
on the isolation of small molecules which mimic the function of
proteins that stabilise p53. Karen Vousden (Frederick) described
this approach for the identiﬁcation of modulators of p14
Arf and
David Lane (Dundee) for Mdm2 E3 ligase activity modulators.
One exciting aspect of these therapeutic based talks was the
development of combined strategies to target more than one key
pathway in the cell. If anything our previous experience in this ﬁeld
has demonstrated that the complexity of changes present within the
cancer cell require a more intellectual approach to this problem if
we are to overcome it.
TRANSCRIPTIONAL PROFILING
Global analysis of gene expression through microarray analysis was
a common theme throughout the entire meeting. Conventionally,
analysis of differences in expression of genes has been performed
by Northern blot analysis or quantitative PCR of reverse tran-
scribed RNA. However, with the advent of DNA microarray
technology it is now possible to compare patterns of global gene
expression simultaneously rather than focusing on individual genes,
thus facilitating a more inclusive experimental approach to study-
ing gene transcription on a genome wide scale. In cancer, this
technology is very powerful because of the multi-step nature of
tumorigenesis where a number of genes must be disrupted for
malignancy. Therefore, using microarray hybridisation analysis this
complex pattern of gene expression can be monitored simultan-
eously. This will allow the classiﬁcation of tumours according to
their gene expression proﬁles and has the potential for the diagno-
sis of cancer and prediction of responses to therapy.
Microarray analysis has now become common practice in many
research laboratories, however one of the major challenges with this
technology is still the interpretation of such complex and vast data
sets. David Botstein (Stanford, CA, USA) and others have used
clustering techniques to compare patterns of gene expression to
each other and to combine patterns that are the most similar (hier-
archical clustering). For example, clustering genes that have similar
expression patterns during cell cycle progression into a phase
ordered map reveals clusters of periodicity allowing the assignment
of different clusters of genes into different stages of the cell cycle (a
so-called ‘phasogram’). This has the added advantage of allowing
the function of previously unknown genes to be inferred based
on clustering with other genes.
In cancer tissue samples, microarray analysis and clustering
algorithms have also been used to classify tumours in a biolo-
gically signiﬁcant way based on their expression proﬁles, often
correlating with clinical outcomes (‘class prediction’). Todd Golub
(Boston, MA, USA) has extended this approach using DNA
microarrays to subclassify human acute leukaemias. Acute
lymphoblastic leukaemia (ALL) and acute myeloid leukaemia
(AML) are molecularly distinct but morphologically similar result-
ing in diagnostic problems. The correct diagnosis of ALL and
AML is critical for successful treatment and to minimise toxicity
since different chemotherapy regimens are used to treat each class.
Using DNA microarrays, these tumours were distinguished from
each other at the gene expression level. Furthermore, ALL
subgroups could be further classiﬁed according to chromosomal
rearrangement status at the MLL gene, which comprise a distinct
type of acute leukaemias which share characteristics of both ALL
and AML. ALLs harbouring MLL rearrangements were shown to
differ by greater than 1000 genes. By applying clustering algo-
rithms to the data, three groups of genes which were
differentially expressed were found, distinguishing MLL from
ALL and AML.
This ability to sub-classify leukaemia, and other cancers such as
breast and lung, according to their gene expression proﬁle has
enormous clinical potential in the diagnosis of cancer and also in
the prediction of the response to chemotherapy. Indeed, micro-
arrays are currently being tested for their use in a clinical setting
to predict the optimal chemotherapeutic programme for individual
patients. Edwin Clark (Cambridge, MA, USA) described the use of
pharmacogenomics to study the global gene expression in relation
to therapeutic response. As a proof of concept, 51 ovarian cancer
tissues were proﬁled retrospectively for the expression of 30000
human genes by microarray analysis to identify expression markers
which correlate with clinical outcome in response to a combination
treatment of taxol and platinum. Using a series of clustering
algorithms, Clark was able to identify genomic markers which
predicted response to therapy with an accuracy of 85–95%, thus
allowing alternative therapy and care for those patients who were
predicted to be ‘non-responders’ to taxol and platinum treatment.
It is now becoming more realistic to imagine that the implemen-
tation of DNA microarray based diagnoses to a single patient could
become routine. However, several problems are associated with this
type of analysis in the clinical setting, such as high cost, the
complexity of the techniques involved as well as the inherent
instability of the RNA molecule. Joe Gray (San Francisco, CA,
USA) described a relatively new technique which may overcome
at least one of these problems; namely the reliance on good quality
RNA. He described using DNA to perform quantitative measure-
ments of DNA copy number in breast cancer by array
comparative genomic hybridisation (CGH). Genomic instability is
a hallmark of cancer and changes in copy number of some genes
occur as tumours more to more invasive phenotypes. The length
of the telomere plays an important role in development of genomic
instability, the transition of tumours through telomeric crisis
results in structural changes in the chromosome and genomic
instability. In view of the random nature of chromosomal instabil-
ity resulting from translocations, mitotic breaks and end-to-end
fusions of chromosomes during telomeric crisis, most individual
cancers are highly variable in terms of the numbers and types of
genome abnormalities involved. This poses a big challenge for
conventional genome copy number analysis using CGH and ﬂuor-
escent in-situ hybridisation (FISH) because this technique is too
labour intensive to apply across the whole genome. Array CGH
by comparison has the potential to cover much of the genome
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gene ampliﬁcations and deletions. Gray’s recent data using a 500
element BAC array has highlighted the variability of abnormalities
between primary breast tumours which are clinically similar,
however a number of genes do crop up frequently, and these
may represent attractive targets for therapeutic intervention. For
example, CMYC, ERBB2 and CCND1 are ampliﬁed in more than
20% of advanced breast cancers and they are all currently being
investigated for targeted therapeutics to speciﬁcally knock out their
functions. However, the spectrum of genomic abnormalities found
using the CGH array system varied substantially among tumours
extending the idea for personalised therapy to be used in the clinic.
Gray also showed that there was good correlation between genome
copy number and gene expression across a panel of 60 cell lines
establishing the relevance of this technique to gene expression
within the cell.
It is clear that the introduction of microarray-based technology
into the ﬁeld of cancer research has greatly accelerated our under-
standing of the processes involved in the development of tumours
by allowing the simultaneous monitoring of the gene expression of
thousands of genes. This will inevitably result in better diagnosis
and novel therapies to target aberrantly expressed genes in complex
biological processes.
Whilst we are still a long way from appreciating all of the
complex changes in gene expression that contribute to the cancer
cell phenotype, the enthusiasm generated during this meeting
provided enlightening prospects for unique strategies to fully
comprehend and more importantly combat cancer.
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